Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI technique could end guesswork in brain tumor Follow-Up

NCT ID NCT07687277

Diagnosis Sponsor: Lanzhou University Second Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests whether a special type of MRI scan can tell the difference between actual tumor growth and harmless treatment-related changes in people who have had surgery for a type of brain cancer called glioma. After treatment, it's often hard to know if a new spot on a scan means the cancer is coming back or is just a temporary reaction. The researchers will use two advanced MRI techniques—3D-ASL and time-dependent diffusion MRI—to measure blood flow and water movement in the brain. If the method works, it could help doctors make better decisions without needing invasive biopsies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Multiparametric MRI (3D-ASL and TDD-MRI)
What this could lead to
If successful, this imaging method could help doctors accurately tell whether a brain tumor is growing or just reacting to treatment, reducing unnecessary surgeries or therapies.
What could go wrong
This is a small, early-stage study. The technique may not be accurate enough to replace current methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

75 people

The number who actually took part.

Started

Mar 2024

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with histopathologically confirmed glioma who develop suspected tumor progression during postoperative follow-up at Lanzhou University Second Hospital and undergo routine MRI, three-dimensional arterial spin labeling (3D-ASL), and time-dependent diffusion MRI (TDD-MRI).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Histopathologically confirmed glioma. * Received standard postoperative treatment or routine clinical treatment. * New or enlarged contrast-enhancing lesion on follow-up MRI suggestive of tumor progression. * Able to undergo routine MRI, three-dimensional arterial spin labeling (3D-ASL), and time-dependent diffusion MRI (TDD-MRI). * MRI image quality sufficient for image processing, registration, lesion segmentation, and quantitative parameter extraction. * Written informed consent provided by the participant or legally authorized representative. Exclusion Criteria: * Incomplete clinical, pathological, or imaging follow-up data. * MRI images with severe motion artifacts, susceptibility artifacts, or geometric distortion affecting image analysis. * Failure to complete routine MRI, 3D-ASL, or TDD-MRI examinations according to the study protocol. * Lesions too small or poorly defined for reliable three-dimensional volume-of-interest delineation and parameter extraction. * Any other condition judged by the investigators to make participation inappropriate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain neoplasms are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain neoplasms GLIOMA

Contacts and locations

Locations

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, 730030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.